Kardigan, Inc. KARD
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -34.91%
- 1 year
- -34.91%
- Market cap
- 1.34B
- EPS (ttm)
- -10.65
- Shares out
- 93.50M
- Forward P/E
- -3.48
- YTD return
- -34.91%
- 1-year return
- -34.91%
- Volume
- 545.03K
- Avg volume
- 564.87K
- Open
- 14.23
- Previous close
- 14.21
- Day's range
- 13.97 – 15.19
- 52-week range
- 12.23 – 27.00
- Analysts
- Strong Buy
- Price target
- 41.00 (+186.3%)
- Earnings date
- Nov 10, 2026
2Y -7.65 (-34.77%)
Key statistics
- Enterprise value
- 744.44M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 597.60M
- Total debt
- 13.35M
- Return on equity
- 0.00%
- Short % of float
- 6.65%
- 50-day average
- 16.20
- 200-day average
- 18.93
Analyst view
Consensus: strong buy
- Target (low)
- 25.00
- Target (mean)
- 41.00
- Target (high)
- 50.00
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -1.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | -0.99105 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.67534 | -2.88 | -2.20 | -326.45% |
| May 26, 2026 | Mar 31, 2026 | — | -3.86 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Oct 22, 2026 | Baird | init | — | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 12, 2026 | UBS | init | — | Buy |
| Aug 25, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 13, 2026 | TD Cowen | init | — | Buy |
About Kardigan, Inc.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kardigan.bio
News
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday 
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More 
Cantor Fitzgerald Initiates Coverage On Kardigan with Overweight Rating, Announces Price Target of $50 
This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
Baird Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $43 
UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25
Your note
Sign in to keep a note on KARD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XIII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 21, 2026 | 0 |
| BERNS PAUL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 21, 2026 | 0 |
| EDELBERG JAY M.D., PH.D. | Officer | Stock Award(Grant) | Jun 16, 2026 | 4,643,170 |
| GIANAKAKOS TOM ANASTASIOS | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 16, 2026 | 0 |
| HRTG GPE, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 21, 2026 | 0 |
| JAHN BRIANNE | Chief Financial Officer | Stock Award(Grant) | Jun 16, 2026 | 79,640 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HRTG GPE, LLC | 18.09% | 16,917,034 | 242.25M | Jun 29, 2026 |
| FMR, LLC | 9.53% | 8,909,066 | 127.58M | Jun 29, 2026 |
| Perceptive Advisors Llc | 8.77% | 8,200,662 | 117.43M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 4.50% | 4,207,130 | 60.25M | Jun 29, 2026 |
| Capital Research Global Investors | 3.85% | 3,598,942 | 51.54M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 1.92% | 1,790,734 | 25.64M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 3.77% | 3,525,648 | 50.49M | Sep 29, 2026 |
| Fidelity Contrafund | 1.34% | 1,250,535 | 17.91M | Aug 30, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.88% | 823,598 | 11.79M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.79% | 737,233 | 10.56M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.79% | 736,283 | 10.54M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 0.69% | 645,684 | 9.25M | Jun 29, 2026 |